Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist

European Journal of Pharmacology

Volumn 499, Issue 1-2, 2004, Pages 107-116

  Neilan, Claire L ^a   Husbands, Stephen M ^b   Breeden, Simon ^c   Ko, M C ^a   Aceto, Mario D ^d   Lewis, John W ^b   Woods, James H ^a   Traynor, John R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b University of Bath   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

(Monkey); (Mouse); Agonism; Antagonism; Antinociception; mu opioid receptor

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ANTINOCICEPTIVE AGENT; BREMAZOCINE; BRIDGED COMPOUND; BU 72; BUPRENORPHINE; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; FENTANYL; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINAN DERIVATIVE; MORPHINE; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; PYRROLIDINOMORPHINAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GUINEA PIG; MALE; MONKEY; MOUSE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION;

ANALGESICS; ANIMALS; BINDING, COMPETITIVE; BUPRENORPHINE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUINEA PIGS; ILEUM; MACACA MULATTA; MALE; MICE; MICE, INBRED ICR; MORPHINANS; MORPHINE; MUSCLE CONTRACTION; PAIN; PAIN MEASUREMENT; PYRROLES; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SULFUR RADIOISOTOPES; TIME FACTORS; TRITIUM; VAS DEFERENS;

EID: 19344377012     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.097     Document Type: Article

References (41)

1. M.D. Aceto, L.S. Harris, and E.R. Bowman Etorphines: μ-opioid receptor-selective antinociception and low physical dependence capacity Eur. J. Pharmacol. 338 1997 215 223
2. J.A. Bell, and J.C. Schaeffer Long-term agonist effects of congeners of etorphine suggest interfacial location of mu opioid recognition site Abstr.-Soc. Neurosci. 23 479 1997 9
3. K.W. Bentley, and D.G. Hardy Novel analgesics and molecular rearrangements in the morphine-thebaine group: III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylmorphine and -narcodeine J. Am. Chem. Soc. 89 1967 3281 3292
4. W.K. Bickel, and L. Amass Buprenorphine treatment of opioid dependence: a review Exp. Clin. Psychopharmacol. 3 1995 477 489
5. L.S. Brady, M. Herkenham, J.B. Long, and R.B. Rothman Chronic morphine increases μ-opiate receptor binding in rat brain: a quantitative autoradiographic study Brain Res. 477 1989 382 386
6. W. Brandt, A. Barth, and H.-D. Holtje A new consistent model explaining structure (conformation)-activity relationships of opiates with μ-selectivity Drug Des. Discov. 10 1993 257 283
7. J.H. Broadbear, S.S. Negus, E.R. Butelman, B.R. deCosta, and J.H. Woods Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay Psychopharmacology 115 1994 311 319
8. J.H. Broadbear, T.L. Sumpter, T.F. Burke, S.M. Husbands, J.W. Lewis, J.H. Woods, and J.R. Traynor Methocinnamox is a potent, long-lasting and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, β-funaltrexamine and β-chlornaltrexamine J. Pharmacol. Exp. Ther. 294 2000 933 940
9. D.C. Broom, L. Gou, A. Coop, S.M. Husbands, J.H. Lewis, J.H. Woods, and J.R. Traynor BU48: a novel buprenorphine analog that exhibits δ-opioid-mediated convulsions but not delta-mediated antinociception in mice J. Pharmacol. Exp. Ther. 294 2000 1195 1200
10. D.C. Broom, J.F. Nitsche, J.E. Pintar, K.C. Rice, J.H. Woods, and J.R. Traynor Comparison of receptor mechanisms and efficacy requirements for δ-agonist induced convulsive activity and antinociception in mice J. Pharmacol. Exp. Ther. 303 2002 723 729
11. A. Cowan, J.C. Doxey, and E.J.R. Harry The animal pharmacology of buprenorphine: an oripavine analgesic agent Br. J. Pharmacol. 60 1977 547 554
12. A. Cowan, J.W. Lewis, and I.R. MacFarlane Agonist and antagonist properties of buprenorphine, a new antinociceptive agent Br. J. Pharmacol. 60 1977 537 545
13. L.A. Dykstra, and J.H. Woods A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys J. Pharmacol. Methods 15 1986 263 269
14. N.B. Eddy, and D. Leimbach Synthetic analgesics: II. Dithienylbutenyl- and dithienylbutylamines J. Pharmacol. Exp. Ther. 107 1953 385
15. C. France, A.E. Jacobson, and J.H. Woods Discriminative stimulus effects of reversible and irreversible opiate antagonists: morphine, oxymorphazone and buprenorphine J. Pharmacol. Exp. Ther. 230 1984 652 657
16. P.J. Fudala, and R.E. Johnson Clinical efficacy studies of buprenorphine for the treatment of opiate dependence A. Cowan J.W. Lewis Buprenorphine: Combatting Drug Abuse with a Unique Opioid 1995 Wiley-Liss New York 213 219
17. J.M. Hambrook, and M.J. Rance The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics H.W. Kosterlitz Opiates and Endogenous Opioid Peptides 1976 Elsevier Amsterdam 295 301
18. H. Houshyar, I.J. McFadyen, J.H. Woods, and J.R. Traynor Antinociceptive and other behavioral effects of the steroid SC17599 are mediated by the μ-opioid receptor Eur. J. Pharmacol. 395 2000 121 128
19. J. Hughes, H.W. Kosterlitz, and F.M. Leslie Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics Br. J. Pharmacol. 53 1975 371 381
20. S.M. Husbands, and J.W. Lewis Morphinan cyclic imines and pyrrolidines containing a constrained phenyl group: high affinity opioid agonists Bioorganic Med. Chem. Letters 5 1995 2969 2974
21. S.M. Husbands, C.L. Neilan, J. Broadbear, P. Grundt, S. Breeden, M.D. Aceto, J.H. Woods, J.W. Lewis, and J.R. Traynor A bridged pyrrolomorphinan with potent, long-lasting κ-opioid agonism and delayed opioid antagonism Eur. J. Pharmacol 2003 (submitted for publication)
22. M. Johnson, P.R. Butchers, R.A. Coleman, A.T. Nials, P. Strong, M.J. Sumner, C.J. Vardey, and C.J. Whelan The pharmacology of salmeterol Life Sci. 52 1993 2131 2143
23. J. Kamei, T. Suzuki, and H. Nagase Agonist and antagonist properties of dihydroetorphine for mu-opioid receptors in mice Neurosci. Lett. 215 1996 87 90
24. R. Koster, M. Anderson, and E.J. Debeer Acetic acid for analgesic screening Fed. Proc. 18 1959 412
25. K.O. Lee, H. Akil, J.H. Woods, and J.R. Traynor Differential binding properties of oripavines at cloned mu- and delta-opioid receptors Eur. J. Pharmacol. 378 1999 323 330
26. O.H. Lowry, N.G. Rosenberg, A.L. Farr, and R.J. Randell Protein measurement with the Folin phenol reagent J. Biol. Chem. 139 1951 265 275
27. J.P. McLaughlin, K.P. Hill, Q. Jiang, A. Sebastian, S. Archer, and J.M. Bidlack Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of μ-selective agonist and antagonist activity J. Pharmacol. Exp. Ther. 289 1999 304 311
28. W.D.M. Paton, and E.S. Vizi The inhibitory action of noradrenaline and adrenaline in acetylcholine output on guinea-pig longitudinal muscle strip Br. J. Pharmacol. 35 1969 10 29
29. J. Pearl, and L.S. Harris Inhibition of writhing by narcotic antagonists J. Pharmacol. Exp. Ther. 154 1966 319 323
30. N.G. Piggot, I. Derrick, H.A. Moynihan, S.M. Husbands, and J.W. Lewis Molecular modeling of fumaramido and cinnamoylamido derivatives in epoxy-morphinans. Correlation with pharmacological profiles Analgesia 1 1995 4 6
31. P.S. Portoghese, and A.E. Takemori Different receptor sites mediate opioid agonism and antagonism J. Med. Chem. 26 1983 1341 1348
32. A. Sebastian, J.M. Bidlack, Q. Jiang, D. Deecher, M. Teitler, S.D. Glick, and S. Archer 14β-p-Nitrocinnamoylamino-7,8-dihydromorphinones and their codeinone analogues: synthesis and receptor activity J. Med. Chem. 36 1993 3154 3160
33. R.J. Tallarida, and R.B. Murray Manual of Pharmacological Calculations with Computer Programs 1987 Springer-Verlag New York
34. P. Tao, P. Law, and H.H. Loh Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment J. Pharmacol. Exp. Ther. 240 1987 809 816
35. A. Tempel, J. Habas, W. Paredes, and G.A. Barr Morphine-induced down regulation of μ-opioid receptors in neonatal rat brain Dev. Brain Res. 41 1988 129 133
36. 35]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells Mol. Pharmacol. 47 1995 848 854
37. J.R. Traynor, L. Guo, A. Coop, J.L. Lewis, and J.H. Woods Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C20 hydroxyl group J. Pharmacol. Exp. Ther. 291 1999 1093 1099
38. M.B. Tyers A classification of opiate receptors that mediate antinociception in animals Br. J. Pharmacol. 69 1980 503 512
39. J.H. Woods, J.W. Lewis, G. Winger, E. Butelman, J. Broadbear, and G. Zernig Methoclocinnamox: a μ partial agonist with pharmacotherapeutic potential for heroin abuse NIDA Res. Monogr. 147 1995 195 219
40. B.C. Yoburn, B. Billings, and A. Duttaroy Opioid receptor regulation in mice J. Pharmacol. Exp. Ther. 265 1993 314 320
41. 35S] GTPγS binding to membranes: determination of potencies and efficacies of ligands J. Pharmacol. Exp. Ther. 282 1997 676 684